目的 探討通竅鼻炎膠囊聯(lián)合孟魯司特鈉片治療變應性鼻炎的臨床療效。方法 選取2019年6月-2021年4月天津市第四中心醫(yī)院收治的120例變應性鼻炎患者作為研究對象，全部患者按照隨機數(shù)字表法分為對照組和治療組，每組各60例。對照組患者口服孟魯司特鈉片，10 mg/次，1次/d。治療組患者在對照組治療的基礎(chǔ)上口服通竅鼻炎膠囊，2.0 g/次，3次/d。兩組患者連續(xù)治療4周。觀察兩組的臨床療效，比較兩組患者的臨床癥狀體征評分、鼻腔容積、最小截面積、鼻阻力。檢查兩組治療前后血清嗜酸性細胞陽離子蛋白（ECP）、白細胞介素-33（IL-33）、特異性IgE（sIgE）水平。結(jié)果 治療后，治療組患者的總有效率為95.00%，對照組患者總有效率為83.33%，兩組有明顯差異（P<0.05）。治療后，兩組鼻癢評分、鼻塞評分、流涕評分、噴嚏評分、體征評分顯著降低（P<0.05），且治療組鼻癢評分、鼻塞評分、流涕評分、噴嚏評分、體征評分降低更明顯（P<0.05）。治療后，兩組的最小截面積、鼻阻力明顯減少，鼻腔容積明顯升高（P<0.05）；治療后，治療組的最小截面積、鼻阻力低于對照組，鼻腔容積高于對照組（P<0.05）。治療后，兩組的血清ECP、IL-33、sIgE水平顯著降低（P<0.05），治療組血清ECP、IL-33、sIgE水平較對照組降低更明顯（P<0.05）。結(jié)論 通竅鼻炎膠囊聯(lián)合孟魯司特鈉片治療變應性鼻炎具有較好的臨床療效，可有效改善患者的鼻腔癥狀和臨床癥狀體征，減輕炎癥反應。

Objective To investigate the clinical efficacy of Tongqiao Biyan Capsules combined with Montelukast Sodium Tablets in treatment of allergic rhinitis. Methods Patients (120 cases) with allergic rhinitis in Tianjin Fourth Central Hospital from June 2019 to April 2021 were divided into control and treatment groups according to the random number table method, and each group had 60 cases. Patients in the control group were po administered with Montelukast Sodium Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Tongqiao Biyan Capsules on the basis of the control group, 2.0 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the clinical symptoms score, signs score, nasal volume, minimum cross-sectional area, and nasal resistance in two groups were compared. The serum levels of ECP, IL-33, and sIgE were measured before and after treatment in two groups. Results After treatment, the total effective rate was 95.00% in the treatment group, and 83.33% in the control group, and there was significant difference between two groups (P<0.05). After treatment, the scores of nasal itching, runny nose, sneezing, nasal obstruction, and signs, and signs scores in two groups were significantly decreased (P<0.05), and the symptoms scores and signs scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the nasal resistance and minimum cross-sectional area in two groups were significantly decreased, but the nasal cavity volume in two groups were significantly increased (P<0.05). After treatment, the nasal resistance and minimum cross-sectional area of the treatment group were lower than those of the control group, but the nasal cavity volume of the treatment group was higher than that of the control group (P<0.05). After treatment, the serum levels of ECP, IL-33, and sIgE in two groups were significantly lower (P<0.05), and the serum levels of ECP, IL-33, and sIgE in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Tongqiao Biyan Capsules combined with Montelukast Sodium Tablets has clinical curative effect in treatment of allergic rhinitis, can effectively improve nasal symptoms, clinical symptoms and signs, and reduce inflammatory reaction.

R976

天津市衛(wèi)生健康委員會、天津市中醫(yī)藥管理局中醫(yī)中西醫(yī)結(jié)合科研課題（2019129）